αβ T Cell Receptor Transfer to γδ T Cells Generates Functional Effector Cells without Mixed TCR Dimers In Vivo

被引:49
作者
van der Veken, Lars T. [1 ]
Coccoris, Miriam [2 ]
Swart, Erwin [2 ]
Falkenburg, J. H. Frederik [1 ]
Schumacher, Ton N. [2 ]
Heemskerk, Mirjam H. M. [1 ]
机构
[1] Leiden Univ, Med Ctr, Dept Hematol, Lab Expt Hematol, NL-2300 RC Leiden, Netherlands
[2] Netherlands Canc Inst, Div Immunol, NL-1066 CX Amsterdam, Netherlands
关键词
DONOR LEUKOCYTE INFUSIONS; DEFICIENT MICE; INTESTINAL EPITHELIUM; CANCER REGRESSION; GENE-TRANSFER/; TUMOR-ANTIGEN; LYMPHOCYTES; THERAPY; IMMUNOTHERAPY; RESISTANCE;
D O I
10.4049/jimmunol.182.1.164
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The successful application of T cell-based immunotherapeutic applications depends on the availability of large numbers of T cells with the desired Ag specificity and phenotypic characteristics. Engineering of TCR-transferred T lymphocytes is an attractive strategy to obtain sufficient T cells with an Ag specificity of choice. However, the introduction of additional TCR chains into T cells leads to the generation of T cells with unknown specificity, due to the formation of mixed dimers between the endogenous and introduced TCR chains. The formation of such potentially autoaggressive T cells may be prevented by using gamma delta T cells as recipient cells, but the in vivo activity of such TCR-engineered gamma delta T cells has not been established. In the present study, we have investigated the in vivo functionality of TCR-transduced gamma delta T cells, in particular their Ag specific proliferative capacity, Ag specific reactivity, in vivo persistence, and their capacity to mount recall responses. The results demonstrate that alpha beta TCR engineering of gamma delta T cells forms a feasible strategy to generate Ag-specific effector T cells that do not express mixed TCR dimers. In view of increasing concerns on the potential autoimmune consequences of mixed TCR dimer formation, the testing of alpha beta TCR engineered gamma delta T cells in clinical trials seems warranted. The Journal of Immunology, 2009, 182: 164-170.
引用
收藏
页码:164 / 170
页数:7
相关论文
共 50 条
[1]  
ASAMOW DM, 1988, CELL, V55, P837
[2]   Phase-I study of Innacell γδ™, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma [J].
Bennouna, Jaafar ;
Bompas, Emmanuelle ;
Neidhardt, Eve Marie ;
Rolland, Frederic ;
Philip, Irene ;
Galea, Celine ;
Salot, Samuel ;
Saiagh, Soraya ;
Audrain, Marie ;
Rimbert, Marie ;
Micheaux, Sylvie Lafaye-de ;
Tiollier, Jerome ;
Negrier, Sylvie .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2008, 57 (11) :1599-1609
[3]   In vitro expansion of gamma delta T cells with anti-myeloma cell activity by Phosphostim and IL-2 in patients with multiple myeloma [J].
Burjanadze, Maka ;
Condomines, Maud ;
Reme, Thierry ;
Quittet, Philippe ;
Latry, Pascal ;
Lugagne, Cecile ;
Romagne, Francois ;
Morel, Yanis ;
Rossi, Jean Francois ;
Klein, Bernard ;
Lu, Zhao Yang .
BRITISH JOURNAL OF HAEMATOLOGY, 2007, 139 (02) :206-216
[4]  
Clay TM, 1999, J IMMUNOL, V163, P507
[5]   Long-term functionality of TCR-transduced T cells in vivo [J].
Coccoris, Miriam ;
Swart, Erwin ;
de Witte, Moniek A. ;
van Heijst, Jeroen W. J. ;
Haanen, John B. A. G. ;
Schepers, Koen ;
Schumacher, Ton N. M. .
JOURNAL OF IMMUNOLOGY, 2008, 180 (10) :6536-6543
[6]   Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation [J].
Collins, RH ;
Shpilberg, O ;
Drobyski, WR ;
Porter, DL ;
Giralt, S ;
Champlin, R ;
Goodman, SA ;
Wolff, SN ;
Hu, W ;
Verfaillie, C ;
List, A ;
Dalton, W ;
Ognoskie, N ;
Chetrit, A ;
Antin, JH ;
Nemunaitis, J .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (02) :433-444
[7]   Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes [J].
Cooper, LJN ;
Kalos, M ;
Lewinsohn, DA ;
Riddell, SR ;
Greenberg, PD .
JOURNAL OF VIROLOGY, 2000, 74 (17) :8207-8212
[8]   TCR gene therapy of spontaneous prostate carcinoma requires in vivo T cell activation [J].
de Witte, Moniek A. ;
Bendle, Gavin M. ;
van den Boom, Marly D. ;
Coccoris, Miriam ;
Schell, Todd D. ;
Tevethia, Satvir S. ;
van Tinteren, Harm ;
Mesman, Elly M. ;
Song, Ji-Ying ;
Schumacher, Ton N. M. .
JOURNAL OF IMMUNOLOGY, 2008, 181 (04) :2563-2571
[9]   Targeting self-antigens through allogeneic TCR gene transfer [J].
de Witte, Moniek A. ;
Coccoris, Miriam ;
Wolkers, Monika C. ;
van den Boom, Marly D. ;
Mesman, Elly M. ;
Song, Ji-Ying ;
van der Valk, Martin ;
Haanen, John B. A. G. ;
Schumacher, Ton N. M. .
BLOOD, 2006, 108 (03) :870-877
[10]   Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma [J].
Dudley, ME ;
Wunderlich, JR ;
Yang, JC ;
Sherry, RM ;
Topalian, SL ;
Restifo, NP ;
Royal, RE ;
Kammula, U ;
White, DE ;
Mavroukakis, SA ;
Rogers, LJ ;
Gracia, GJ ;
Jones, SA ;
Mangiameli, DP ;
Pelletier, MM ;
Gea-Banacloche, J ;
Robinson, MR ;
Berman, DM ;
Filie, AC ;
Abati, A ;
Rosenberg, SA .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (10) :2346-2357